Including Headache News Today

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call was held ...

McKinsey Jordan/Stocksy In the effort to protect the population against COVID-19 infection, more than one million doses of the COVID-19 vaccine are being given every day in the United States, and that number continues to climb as production and distribution improve. That means, according to Bloomberg, that more Americans have received their first dose of the vaccine than have tested positive for the virus since the pandemic began in early 2020. A sample of approximately 2 million people out o...